

PD-L1 expression in cancer patients receiving anti PD-1 and meta-analysis

Critical Reviews in Oncology/Hematology

100, 88-98

DOI: [10.1016/j.critrevonc.2016.02.001](https://doi.org/10.1016/j.critrevonc.2016.02.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
2	Immuntherapie bei Lungenkrebs. Karger Kompass Onkologie, 2016, 3, 60-68.	0.0	0
3	Immunoproteasomes and immunotherapyâ€”a smoking gun for lung cancer?. Journal of Thoracic Disease, 2016, 8, E558-E563.	0.6	7
4	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget, 2016, 7, 77404-77415.	0.8	139
5	Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. Journal of Gastrointestinal Oncology, 2016, 7, 713-720.	0.6	45
6	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0160485.	1.1	33
7	Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS ONE, 2016, 11, e0160882.	1.1	93
8	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget, 2016, 7, 74350-74361.	0.8	35
9	Wnt/ β -catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treatment Reviews, 2016, 49, 1-12.	3.4	85
10	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 313-320.	1.0	4
11	Editorial: Blockade of PD-1 and PD-L1 restores defective innate immune responses in leukocytes from septic humans. Journal of Leukocyte Biology, 2016, 100, 1229-1231.	1.5	1
12	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 2016, 11, 385-390.	0.8	20,872
13	Immunotherapy for Lung Cancer. Oncology Research and Treatment, 2016, 39, 360-368.	0.8	13
14	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. Expert Opinion on Biological Therapy, 2016, 16, 895-901.	1.4	20
15	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	6.9	271
16	Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078.	6.6	418
17	Molecular mechanisms of <sc>HLA</sc> class Iâ€”mediated immune evasion of human tumors and their role in resistance to immunotherapies. Hla, 2016, 88, 213-220.	0.4	43
18	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology, 2016, 5, e1213934.	2.1	65

#	ARTICLE	IF	CITATIONS
19	PD-L1 in melanoma: facts and myths. <i>Melanoma Management</i> , 2016, 3, 187-194.	0.1	11
20	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <i>Protein and Cell</i> , 2016, 7, 866-877.	4.8	44
22	Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. <i>Lung Cancer</i> , 2017, 107, 1-13.	0.9	30
23	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 357-368.	1.1	11
24	Tumor-Targeting <i>Salmonella typhimurium</i> A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	1.2	53
25	Immunoprofiling as a predictor of patient's response to cancer therapy—promises and challenges. <i>Current Opinion in Immunology</i> , 2017, 45, 60-72.	2.4	39
26	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. <i>European Journal of Cancer</i> , 2017, 76, 1-7.	1.3	49
27	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 124-132.	2.0	93
28	Very low expression of PD-L1 in medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2017, 24, L35-L38.	1.6	34
29	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 851-861.	1.2	82
30	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
31	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
32	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
33	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1339856.	2.1	8
34	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017, 22, 1266-1273.	3.2	48
35	Mechanisms of Resistance to Immune Checkpoint Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 109-128.	0.9	26
36	New concepts of personalized therapy in salivary gland carcinomas. <i>Oral Oncology</i> , 2017, 68, 103-113.	0.8	36
37	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 207-216.	1.2	70

#	ARTICLE	IF	CITATIONS
38	Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 20657-20668.	1.6	59
39	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. <i>European Journal of Cancer</i> , 2017, 84, 290-303.	1.3	112
40	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
41	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.3	23
42	Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations. <i>Pharmaceutical Medicine</i> , 2017, 31, 217-233.	1.0	4
43	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <i>Human Pathology</i> , 2017, 66, 13-33.	1.1	46
44	The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 82.	0.4	13
45	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
46	PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. <i>Pathology</i> , 2017, 49, 499-505.	0.3	39
47	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. <i>Brain Tumor Pathology</i> , 2017, 34, 8-19.	1.1	22
48	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50)</i> , 2017, 96, 1-6.	0.4	2
49	Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis. <i>International Journal of Biological Markers</i> , 2017, 32, 68-74.	0.7	55
50	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 58457-58468.	0.8	42
51	Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	2
52	Pseudoprogression in lung adenocarcinoma during treatment with nivolumab. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219919.	0.2	11
53	Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1875.	1.8	26
54	Epigenetic Strategies to Boost Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1108.	1.8	29
55	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61

#	ARTICLE	IF	CITATIONS
56	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. <i>Journal of Onco-Nephrology</i> , 2017, 1, 179-187.	0.3	1
57	Circulating Tumor Cells (CTCs) as Biomarker for PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Cancer Science & Therapy</i> , 2017, 09, .	1.7	0
58	Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 31347-31354.	0.8	147
59	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 24644-24651.	0.8	146
60	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. <i>Oncolimmunology</i> , 2018, 7, e1438111.	2.1	119
61	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
62	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , 2018, 95, 38-51.	1.3	9
63	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
64	Reply: Optimizing Strategies for Immune Checkpoint Imaging with Immuno-PET in Preclinical Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 711.2-712.	2.8	0
65	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. <i>Modern Pathology</i> , 2018, 31, 623-632.	2.9	102
66	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	2.0	50
67	PD-1 Blockade in Renal Cell Carcinoma. , 2018, , 345-355.		0
68	Checkpoint inhibitors in breast cancer – Current status. <i>Cancer Treatment Reviews</i> , 2018, 63, 122-134.	3.4	112
69	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018, 29, 301-310.	0.6	98
70	Letter from Japan. <i>Respirology</i> , 2018, 23, 419-420.	1.3	0
71	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10
72	Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors. <i>Medicine (United States)</i> , 2018, 97, e9617.	0.4	56
74	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87

#	ARTICLE	IF	CITATIONS
75	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 124-133.	0.5	52
76	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
77	Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225048.	0.2	14
79	Dramatic Response of a PD-L1â€“Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	1.5	16
80	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. <i>Journal of Cancer</i> , 2018, 9, 4099-4107.	1.2	7
81	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7529-7542.	1.0	29
82	The clinical promise of immunotherapy in triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6823-6833.	0.9	113
83	Organoid Modeling of the Tumor Immune Microenvironment. <i>Cell</i> , 2018, 175, 1972-1988.e16.	13.5	870
84	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
85	Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. <i>Scientific Reports</i> , 2018, 8, 15732.	1.6	23
86	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1041.	1.8	53
87	Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. <i>BioScience Trends</i> , 2018, 12, 412-418.	1.1	13
88	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2018, 86, 81-90.	0.8	95
89	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
90	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
91	HPV â€“ Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
92	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
93	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2018, 119, 193-199.	2.9	21

#	ARTICLE	IF	CITATIONS
94	Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. <i>IScience</i> , 2018, 4, 312-325.	1.9	69
95	Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 313-318.	1.2	17
96	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. <i>Frontiers in Oncology</i> , 2018, 8, 27.	1.3	71
97	Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. <i>Journal of Clinical Medicine</i> , 2018, 7, 163.	1.0	50
98	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	3.2	116
99	Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 410-417.e1.	1.1	109
100	Immune checkpoint receptors: homeostatic regulators of immunity. <i>Hepatology International</i> , 2018, 12, 223-236.	1.9	43
101	PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. <i>American Journal of Dermatopathology</i> , 2018, 40, 647-654.	0.3	42
102	Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma. <i>Case Reports in Ophthalmology</i> , 2018, 9, 348-356.	0.3	25
103	Molecular imaging of T cell co-regulator factor B7-H3 with ⁸⁹ Zr-DS-5573a. <i>Theranostics</i> , 2018, 8, 4199-4209.	4.6	32
105	Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. <i>Pathology Research and Practice</i> , 2018, 214, 1110-1114.	1.0	21
106	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 155-171.	4.2	25
107	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 93-99.	1.1	23
108	Analyzing the percentage of different PD-1 + T cell subsets in peripheral blood and bronchoalveolar lavage fluid of small cell lung cancer patients: A prospective study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 1074-1083.	0.9	2
109	Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986190.	1.4	31
110	PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition. <i>Frontiers in Immunology</i> , 2019, 10, 2022.	2.2	270
111	Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?. <i>Brain Tumor Pathology</i> , 2019, 36, 152-161.	1.1	12
112	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 1667-1678.	1.1	13

#	ARTICLE	IF	CITATIONS
113	Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. <i>Journal of Cancer</i> , 2019, 10, 3070-3078.	1.2	10
114	Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 17-33.	1.1	74
115	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
116	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 962.	1.6	29
117	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73
119	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1683.	1.7	38
120	Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 4194-4201.	1.9	6
121	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
122	PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 806.	1.7	66
123	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 743.	1.0	29
124	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
125	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	1.7	12
126	Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. <i>Journal of Experimental Medicine</i> , 2019, 216, 1525-1541.	4.2	23
127	Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984637.	0.8	48
128	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. <i>Scientific Reports</i> , 2019, 9, 6136.	1.6	124
129	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019, 14, 914-923.	0.5	66
130	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239
131	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32

#	ARTICLE	IF	CITATIONS
132	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
133	YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. <i>Drug Resistance Updates</i> , 2019, 43, 10-28.	6.5	81
134	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. <i>Molecular Cancer</i> , 2019, 18, 54.	7.9	65
135	PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma. <i>Cryobiology</i> , 2019, 87, 86-90.	0.3	14
136	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 16662.	1.6	33
137	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
138	The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 3-10.	0.9	12
139	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. <i>Physics in Medicine and Biology</i> , 2019, 64, 025017.	1.6	22
140	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 722-731.	1.2	22
141	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma—correlation with clinicopathological data and comparison of antibodies. <i>BMC Cancer</i> , 2019, 19, 72.	1.1	32
142	PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 571-584.	1.1	51
143	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186.	0.8	32
144	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 546-554.	1.1	53
145	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
146	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1659093.	2.1	62
147	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
148	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1-12.	4.8	273
149	PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2020, 20, e99-e111.	1.1	10

#	ARTICLE	IF	CITATIONS
150	Association of combined <sc>PD</sc>â€L1 expression and tumourâ€infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 984-994.	1.3	31
151	PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathology Research and Practice, 2020, 216, 152802.	1.0	29
152	Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. Journal of Immunotherapy, 2020, 43, 57-66.	1.2	36
153	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics, 2020, 10, 1708-1718.	4.6	68
154	PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer. Disease Markers, 2020, 2020, 1-7.	0.6	5
155	Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032.	5.2	46
156	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
157	Isolation of DNA Aptamer Targeting PD-1 with an Antitumor Immunotherapy Effect. ACS Applied Bio Materials, 2020, 3, 7080-7086.	2.3	19
158	An increase of CD8+â€T cell infiltration following recurrence is a good prognosticator in HNSCC. Scientific Reports, 2020, 10, 20059.	1.6	34
159	Characterizing heterogeneity of nonâ€small cell lung tumour microenvironment to identify signature prognostic genes. Journal of Cellular and Molecular Medicine, 2020, 24, 14608-14618.	1.6	10
160	Antifade Carbon Dots on a Plasmonic Substrate for Enhanced Protein Detection in Immunotherapy. ACS Sensors, 2020, 5, 4027-4034.	4.0	7
161	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
162	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. American Journal of Surgical Pathology, 2020, 44, 1050-1060.	2.1	34
163	PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Frontiers in Immunology, 2020, 11, 589997.	2.2	45
164	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics, 2020, 12, 758.	2.0	6
165	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Annals of Translational Medicine, 2020, 8, 1095-1095.	0.7	27
166	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 2020, 26, 1141-1151.	3.2	43
167	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	18.1	684

#	ARTICLE	IF	CITATIONS
168	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
169	Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. <i>Diagnostics</i> , 2020, 10, 394.	1.3	4
170	The tumour microenvironment of pituitary neuroendocrine tumours. <i>Frontiers in Neuroendocrinology</i> , 2020, 58, 100852.	2.5	29
171	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 899.	1.3	44
172	The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. <i>Human Immunology</i> , 2020, 81, 254-261.	1.2	14
173	Emerging Role of Circulating Tumor Cells in Gastric Cancer. <i>Cancers</i> , 2020, 12, 695.	1.7	30
174	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 29.	1.3	11
175	Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. <i>Breast Cancer Research</i> , 2020, 22, 69.	2.2	45
176	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020, 12, 361.	1.7	19
177	Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	54
178	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
179	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
180	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020, 59, 652-659.	0.8	28
181	Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 448.	1.8	6
182	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
183	Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103164.	2.0	40
184	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1564-1572.e4.	0.3	20
185	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. <i>Frontiers in Immunology</i> , 2020, 11, 612244.	2.2	31

#	ARTICLE	IF	CITATIONS
186	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
187	SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. <i>Scientific Reports</i> , 2021, 11, 1399.	1.6	37
188	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. <i>Science China Life Sciences</i> , 2021, 64, 1590-1601.	2.3	9
189	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. <i>Cells</i> , 2021, 10, 56.	1.8	14
190	Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110473.	1.1	1
191	Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. <i>Immunotherapy</i> , 2021, 13, 113-123.	1.0	2
192	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021, 13, 746.	1.7	9
193	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
194	Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. <i>Frontiers in Pharmacology</i> , 2021, 12, 572845.	1.6	6
195	Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary. <i>Future Oncology</i> , 2021, 17, 363-369.	1.1	1
196	The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 645069.	1.3	18
197	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. <i>Cancers</i> , 2021, 13, 1256.	1.7	6
198	Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1922.	1.7	29
199	PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. <i>Minerva Respiratory Medicine</i> , 2021, 60, .	0.1	4
200	Explant Modeling of the Immune Environment of Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611365.	1.3	6
201	PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature. <i>Acta Cytologica</i> , 2021, 65, 501-509.	0.7	9
202	Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review. <i>Immunotherapy</i> , 2021, 13, 989-1000.	1.0	7
203	Autophagy controls programmed death ligand 1 expression on cancer cells (Review). <i>Biomedical Reports</i> , 2021, 15, 84.	0.9	12

#	ARTICLE	IF	CITATIONS
204	Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 409.	1.8	9
205	PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis. <i>Cancers</i> , 2021, 13, 4562.	1.7	2
206	Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. <i>Chemical Communications</i> , 2021, 57, 367-370.	2.2	20
207	Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 300-309.	0.6	4
208	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100442.	0.7	14
210	Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216450.	0.2	2
211	PD-L1 Status in Refractory Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0166266.	1.1	47
212	Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0176822.	1.1	64
213	Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. <i>Endocrine-Related Cancer</i> , 2020, 27, R219-R238.	1.6	22
214	Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma. <i>Oncotarget</i> , 2016, 7, 69749-69759.	0.8	20
215	PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. <i>Oncotarget</i> , 2016, 7, 77010-77020.	0.8	44
216	Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis. <i>Oncotarget</i> , 2018, 9, 35343-35355.	0.8	7
217	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	0.8	11
218	Immune Checkpoint Inhibitors: Basics and Challenges. <i>Current Medicinal Chemistry</i> , 2019, 26, 3009-3025.	1.2	286
219	Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer. <i>Current Drug Metabolism</i> , 2019, 20, 880-888.	0.7	5
220	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. <i>Frontiers in Immunology</i> , 2020, 11, 596825.	2.2	53
221	Immunotherapy in Solid Tumors and Gut Microbiota: The Correlationâ€”A Special Reference to Colorectal Cancer. <i>Cancers</i> , 2021, 13, 43.	1.7	17
222	Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. <i>International Journal of Critical Illness and Injury Science</i> , 2017, 7, 177.	0.2	13

#	ARTICLE	IF	CITATIONS
223	Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2021, 11, 1927.	1.3	4
224	Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. , 2017, , 1-20.		0
225	Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. <i>Oncotarget</i> , 2017, 8, 44447-44464.	0.8	1
227	Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. , 2019, , 595-614.		0
228	Immunopathology and Immunotherapy of Melanoma. , 2020, , 305-332.		0
231	Tumor infiltrating lymphocytes in malignant melanoma - allies or foes?. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020, 164, 43-48.	0.2	2
232	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1625-1638.	1.5	10
234	PD-1 ⁺ CXCR5 ⁺ CD4 ⁺ T cells are correlated with the severity of lung adenocarcinoma malignant processes. <i>Scandinavian Journal of Immunology</i> , 2022, 95, .	1.3	0
235	Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 748465.	1.3	12
236	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 759217.	2.2	18
237	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. <i>Nature Communications</i> , 2021, 12, 6726.	5.8	101
238	Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 791411.	1.3	2
239	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. <i>Life</i> , 2022, 12, 229.	1.1	15
240	Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 757432.	1.2	5
241	Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 839756.	2.0	2
242	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. <i>Science Translational Medicine</i> , 2022, 14, eabe8195.	5.8	16
243	Safety and efficacy of mutant neoantigen-specific T-cell treatment combined anti-PD-1 therapy in stage IV solid tumors. <i>Immunotherapy</i> , 2022, , .	1.0	4
244	Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103660.	2.0	4

#	ARTICLE	IF	CITATIONS
245	Identification and validation of Osteopontin and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) for potential immunotherapeutic significance of in lung squamous cell carcinoma. <i>International Immunopharmacology</i> , 2022, 107, 108715.	1.7	6
246	<i>Cutibacterium acnes</i> Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer. <i>Microbiology Spectrum</i> , 2021, 9, e0149721.	1.2	10
247	The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 6272.	1.7	1
248	Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion. <i>Frontiers in Immunology</i> , 2021, 12, 760683.	2.2	4
249	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	1.7	15
264	Precision medicine approaches for treating hepatocellular carcinoma. , 2022, , 287-299.		0
265	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	0.8	29
266	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26
267	The Association of Programmed Cell Death-Ligand 1 Expression with Early Evolution from Adenocarcinoma in Situ to Invasive Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
268	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. <i>Heliyon</i> , 2022, 8, e09474.	1.4	1
269	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2498.	1.7	12
270	Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1364-1371.	1.0	2
271	Epigenetic immunotherapy for cancers: rationales of epigenetic drugs in combination with immunotherapy and advances in clinical trials. <i>Cancer Communications</i> , 2022, 42, 493-516.	3.7	14
272	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	7
273	PD-L1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 151976.	0.6	3
274	Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1747-1754.	1.2	2
275	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
276	Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome. <i>Clinical and Experimental Medicine</i> , 2023, 23, 859-869.	1.9	2

#	ARTICLE	IF	CITATIONS
277	Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World Journal of Clinical Oncology, 2022, 13, 553-566.	0.9	2
278	<scp>Nanoalbuminâ€“prodrug</scp> conjugates prepared via a <scp>thiolationâ€“andâ€“conjugation</scp> method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting <scp>CD8</scp>⁺ Tâ€“cell infiltration. Bioengineering and Translational Medicine, 2023, 8, .	3.9	2
279	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. Clinics and Practice, 2022, 12, 653-671.	0.6	8
281	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. , 2022, , .		0
282	Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic. Journal of Nuclear Medicine, 0, , jnumed.122.264373.	2.8	4
283	Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer. Frontiers in Endocrinology, 0, 13, .	1.5	0
284	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology, 0, 13, .	2.2	83
285	Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. Frontiers in Medicine, 0, 9, .	1.2	2
286	SERS Multiplex Profiling of Melanoma Circulating Tumor Cells for Predicting the Response to Immune Checkpoint Blockade Therapy. Analytical Chemistry, 2022, 94, 14573-14582.	3.2	9
287	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 1003-1014.	2.0	4
288	OncoTheradÂ® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5025-5036.	1.2	3
289	Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathology Research and Practice, 2023, 241, 154241.	1.0	8
290	Gallium-68â€“labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. Clinical Cancer Research, 2023, 29, 581-591.	3.2	8
291	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer, 2022, 22, .	1.1	1
292	Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma. BMC Pulmonary Medicine, 2023, 23, .	0.8	2
293	Present and Future Role of Immune Targets in Acute Myeloid Leukemia. Cancers, 2023, 15, 253.	1.7	2
294	Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy. Biomolecules, 2023, 13, 190.	1.8	4
295	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. International Immunopharmacology, 2023, 117, 109881.	1.7	8

#	ARTICLE	IF	CITATIONS
296	Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplateforms enhances the efficacy of checkpoint blockade immunotherapy. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100784.	4.3	0
297	Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. Frontiers in Immunology, 0, 14, .	2.2	7
298	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
299	The role of dendritic cells in radiation-induced immune responses. International Review of Cell and Molecular Biology, 2023, , .	1.6	1
300	The predictive value of <sc>PD-1</sc> expression in patients with advanced hepatocellular carcinoma treated with <sc>PD-1</sc> inhibitors: A systematic review and meta-analysis. Cancer Medicine, 2023, 12, 9282-9292.	1.3	8
301	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473.	1.0	1